{"id":"standard-dose-standard-xelox-sintilimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Immune-related adverse events (fatigue, hepatotoxicity)"}]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"XELOX is a combination of capecitabine and oxaliplatin that damages cancer cell DNA and prevents replication. Sintilimab is a humanized monoclonal antibody that blocks PD-1 on T cells, preventing tumor cells from suppressing the immune response. Together, they provide both direct cytotoxic effects and immune checkpoint relief to enhance anti-tumor immunity.","oneSentence":"XELOX chemotherapy combined with sintilimab (a PD-1 inhibitor) works by killing cancer cells through chemotoxicity while simultaneously unleashing immune cells to attack tumors by blocking the PD-1 checkpoint.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:36:09.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric or gastroesophageal junction cancer (Phase 3 trial setting)"}]},"trialDetails":[{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT07161115","phase":"PHASE2","title":"Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Longhao Li","startDate":"2025-09-19","conditions":"Rectal Adenocarcinoma","enrollment":60},{"nctId":"NCT06931808","phase":"PHASE4","title":"Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-03-01","conditions":"Localized Advanced Rectal Adenocarcinoma","enrollment":20},{"nctId":"NCT05918094","phase":"PHASE3","title":"Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-04-30","conditions":"Gastric Cancer","enrollment":540},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT05468138","phase":"PHASE2","title":"PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-25","conditions":"MSI-H, PD-1 Immunotherapy, Gastric Cancer","enrollment":141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard dose: standard XELOX + sintilimab","genericName":"Standard dose: standard XELOX + sintilimab","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XELOX chemotherapy combined with sintilimab (a PD-1 inhibitor) works by killing cancer cells through chemotoxicity while simultaneously unleashing immune cells to attack tumors by blocking the PD-1 checkpoint. Used for Gastric or gastroesophageal junction cancer (Phase 3 trial setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}